Collecting more than 3 decades’ worth of data, researchers determined that none of the identified blood biomarkers are accurate enough to take the place of current diagnostic approaches, either due to ...

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...

Hyperuricemia may causally contribute to PAH, positioning uric acid as a potential therapeutic target for treatment and prevention. Mendelian randomization analysis suggests a genetic-level causal ...

Merck recently rolled out its latest campaign focusing on pulmonary arterial hypertension (PAH), a serious and progressive disease that can cause heart failure and lower life expectancy. PAH is a rare ...

After three years, the crown jewel of Merck’s $11.5 billion acquisition of Acceleron is ready to pay dividends. With the FDA’s approval of Winrevair (sotatercept) to treat pulmonary arterial ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Two clinical trials of Merck’s pulmonary arterial hypertension (PAH) drug Winrevair were so conclusive that the studies were halted within the last year because the efficacy of the treatment was ...

A new phase 3 study comparing mono and duo therapies may yield greater guidance and treatment options for children with pulmonary arterial hypertension (PAH). PAH is a rare condition in children, but ...

Patients can “Outnumber PAH” by developing a strong support team, advises an unbranded educational campaign launched by Merck against pulmonary arterial hypertension (PAH), a rare, progressive disease ...